Open Access. Powered by Scholars. Published by Universities.®

Biochemistry, Biophysics, and Structural Biology Commons™

Open Access. Powered by Scholars. Published by Universities.®

2011

Discipline
Institution
Keyword
Publication
Publication Type
File Type

Articles 61 - 90 of 626

Full-Text Articles in Biochemistry, Biophysics, and Structural Biology

Inclusion Of Solvation Free Energy With Molecular Mechanics Energy: Alanyl Dipeptide As A Test Case, Celia Schiffer, James Caldwell, Robert Stroud, Peter Kollman Nov 2011

Inclusion Of Solvation Free Energy With Molecular Mechanics Energy: Alanyl Dipeptide As A Test Case, Celia Schiffer, James Caldwell, Robert Stroud, Peter Kollman

Celia A. Schiffer

A combined force field of molecular mechanics and solvation free energy is tested by carrying out energy minimization and molecular dynamics on several conformations of the alanyl dipeptide. Our results are qualitatively consistent with previous experimental and computational studies, in that the addition of solvation energy stabilizes the C5 conformation of the alanyl dipeptide relative to the C7.

Go to article

Design Of Hiv-1 Protease Inhibitors Active On Multidrug-Resistant Virus, Dominique Surleraux, Herman De Kock, Wim Verschueren, Geert Pille, Louis Maes, Anik Peeters, Sandrine Vendeville, Sandra De Meyer, Hilde Azijn, Rudi Pauwels, Marie-Pierre De Bethune, Nancy King, Moses Prabu-Jeyabalan, Celia Schiffer, Piet Wigerinck Nov 2011

Design Of Hiv-1 Protease Inhibitors Active On Multidrug-Resistant Virus, Dominique Surleraux, Herman De Kock, Wim Verschueren, Geert Pille, Louis Maes, Anik Peeters, Sandrine Vendeville, Sandra De Meyer, Hilde Azijn, Rudi Pauwels, Marie-Pierre De Bethune, Nancy King, Moses Prabu-Jeyabalan, Celia Schiffer, Piet Wigerinck

Celia A. Schiffer

On the basis of structural data gathered during our ongoing HIV-1 protease inhibitors program, from which our clinical candidate TMC114 9 was selected, we have discovered new series of fused heteroaromatic sulfonamides. The further extension into the P2' region was aimed at identifying new classes of compounds with an improved broad spectrum activity and acceptable pharmacokinetic properties. Several of these compounds display an exceptional broad spectrum activity against a panel of highly cross-resistant mutants. Certain members of these series exhibit favorable pharmacokinetic profiles in rat and dog. Crystal structures and molecular modeling were used to rationalize the broad spectrum profile …

Go to article

Pten Enters The Nucleus By Diffusion, Fenghua Liu, Stefan Wagner, Robert Campbell, Jeffrey Nickerson, Celia Schiffer, Alonzo Ross Nov 2011

Pten Enters The Nucleus By Diffusion, Fenghua Liu, Stefan Wagner, Robert Campbell, Jeffrey Nickerson, Celia Schiffer, Alonzo Ross

Celia A. Schiffer

Despite much evidence for phosphatidylinositol phosphate (PIP)-triggered signaling pathways in the nucleus, there is little understanding of how the levels and activities of these proteins are regulated. As a first step to elucidating this problem, we determined whether phosphatase and tensin homolog deleted on chromosome 10 (PTEN) enters the nucleus by passive diffusion or active transport. We expressed various PTEN fusion proteins in tsBN2, HeLa, LNCaP, and U87MG cells and determined that the largest PTEN fusion proteins showed little or no nuclear localization. Because diffusion through nuclear pores is limited to proteins of 60,000 Da or less, this suggests that …

Go to article

Protein Structure Prediction With A Combined Solvation Free Energy-Molecular Mechanics Force Field, Celia Schiffer, James Caldwell, Peter Kollman, Robert Stroud Nov 2011

Protein Structure Prediction With A Combined Solvation Free Energy-Molecular Mechanics Force Field, Celia Schiffer, James Caldwell, Peter Kollman, Robert Stroud

Celia A. Schiffer

Models of protein structure are frequently used to determine the physical characteristics of a protein when the crystal structure is not available. We developed a procedure to optimize such models, by use of a combined solvation free energy and molecular mechanics force field. Appropriately chosen atomic solvation parameters were defined using the criterion that the resulting protein model should deviate least from the crystal structure upon a forty picosecond molecular dynamics simulation carried out using the combined force field. Several tests were performed to refine the set of atomic solvation parameters which best complement the molecular mechanics forces. Four sets …

Go to article

Dynamics Of Preferential Substrate Recognition In Hiv-1 Protease: Redefining The Substrate Envelope, Aysegul Ozen, Turkan Haliloglu, Celia Schiffer Nov 2011

Dynamics Of Preferential Substrate Recognition In Hiv-1 Protease: Redefining The Substrate Envelope, Aysegul Ozen, Turkan Haliloglu, Celia Schiffer

Celia A. Schiffer

Human immunodeficiency virus type 1 (HIV-1) protease (PR) permits viral maturation by processing the gag and gag-pro-pol polyproteins. HIV-1 PR inhibitors (PIs) are used in combination antiviral therapy but the emergence of drug resistance has limited their efficacy. The rapid evolution of HIV-1 necessitates consideration of drug resistance in novel drug design. Drug-resistant HIV-1 PR variants no longer inhibited efficiently, continue to hydrolyze the natural viral substrates. Though highly diverse in sequence, the HIV-1 PR substrates bind in a conserved three-dimensional shape we termed the substrate envelope. Earlier, we showed that resistance mutations arise where PIs protrude beyond the substrate …

Go to article

N88d Facilitates The Co-Occurrence Of D30n And L90m And The Development Of Multidrug Resistance In Hiv Type 1 Protease Following Nelfinavir Treatment Failure, Yumi Mitsuya, Mark Winters, W. Jeffrey Fessel, Soo-Yon Rhee, Leo Hurley, Michael Horberg, Celia Schiffer, Andrew Zolopa, Robert Shafer Nov 2011

N88d Facilitates The Co-Occurrence Of D30n And L90m And The Development Of Multidrug Resistance In Hiv Type 1 Protease Following Nelfinavir Treatment Failure, Yumi Mitsuya, Mark Winters, W. Jeffrey Fessel, Soo-Yon Rhee, Leo Hurley, Michael Horberg, Celia Schiffer, Andrew Zolopa, Robert Shafer

Celia A. Schiffer

Nelfinavir was once one of the most commonly used protease inhibitors (PIs). To investigate the genetic mechanisms of multidrug resistance in protease isolates with the primary nelfinavir resistance mutation D30N, we analyzed patterns of protease mutations in 582 viruses with D30N from 460 persons undergoing HIV-1 genotypic resistance testing at Stanford University Hospital from 1997 to 2005. Three patterns of mutational associations were identified. First, D30N was positively associated with N88D but negatively associated with N88S. Second, D30N and L90M were negatively associated except in the presence of N88D, which facilitated the co-occurrence of D30N and L90M. Third, D30N+N88D+L90M formed …

Go to article

Tmc310911, A Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor, Shows In Vitro An Improved Resistance Profile And Higher Genetic Barrier To Resistance Compared With Current Protease Inhibitors, Inge Dierynck, Herwig Van Marck, Marcia Van Ginderen, Tim Jonckers, Madhavi Nalam, Celia Schiffer, Araz Raoof, Guenter Kraus, Gaston Picchio Nov 2011

Tmc310911, A Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor, Shows In Vitro An Improved Resistance Profile And Higher Genetic Barrier To Resistance Compared With Current Protease Inhibitors, Inge Dierynck, Herwig Van Marck, Marcia Van Ginderen, Tim Jonckers, Madhavi Nalam, Celia Schiffer, Araz Raoof, Guenter Kraus, Gaston Picchio

Celia A. Schiffer

TMC310911 is a novel human immunodeficiency virus type 1 (HIV-1) protease inhibitor (PI) structurally closely related to darunavir (DRV) but with improved virological characteristics. TMC310911 has potent activity against wild-type (WT) HIV-1 (median 50% effective concentration [EC(50)], 14 nM) and a wide spectrum of recombinant HIV-1 clinical isolates, including multiple-PI-resistant strains with decreased susceptibility to currently approved PIs (fold change [FC] in EC(50), >10). For a panel of 2,011 recombinant clinical isolates with decreased susceptibility to at least one of the currently approved PIs, the FC in TMC310911 EC(50) was

Go to article

Cooperative Fluctuations Of Unliganded And Substrate-Bound Hiv-1 Protease: A Structure-Based Analysis On A Variety Of Conformations From Crystallography And Molecular Dynamics Simulations, Nese Kurt, Walter Scott, Celia Schiffer, Turkan Haliloglu Nov 2011

Cooperative Fluctuations Of Unliganded And Substrate-Bound Hiv-1 Protease: A Structure-Based Analysis On A Variety Of Conformations From Crystallography And Molecular Dynamics Simulations, Nese Kurt, Walter Scott, Celia Schiffer, Turkan Haliloglu

Celia A. Schiffer

The dynamics of HIV-1 protease, both in unliganded and substrate-bound forms have been analyzed by using an analytical method, Gaussian network model (GNM). The method is applied to different conformations accessible to the protein backbone in the native state, observed in crystal structures and snapshots from fully atomistic molecular dynamics (MD) simulation trajectories. The modes of motion obtained from GNM on different conformations of HIV-1 protease are conserved throughout the MD simulations. The flaps and 40's loop of the unliganded HIV-1 protease structure are identified as the most mobile regions. However, in the liganded structure these flaps lose mobility, and …

Go to article

Design Of Mutation-Resistant Hiv Protease Inhibitors With The Substrate Envelope Hypothesis, Sripriya Chellappan, G. S. Kiran Kumar Reddy, Akbar Ali, Madhavi Nalam, Saima Anjum, Hong Cao, Visvaldas Kairys, Miguel Fernandes, Michael Altman, Bruce Tidor, Tariq Rana, Celia Schiffer, Michael Gilson Nov 2011

Design Of Mutation-Resistant Hiv Protease Inhibitors With The Substrate Envelope Hypothesis, Sripriya Chellappan, G. S. Kiran Kumar Reddy, Akbar Ali, Madhavi Nalam, Saima Anjum, Hong Cao, Visvaldas Kairys, Miguel Fernandes, Michael Altman, Bruce Tidor, Tariq Rana, Celia Schiffer, Michael Gilson

Celia A. Schiffer

There is a clinical need for HIV protease inhibitors that can evade resistance mutations. One possible approach to designing such inhibitors relies upon the crystallographic observation that the substrates of HIV protease occupy a rather constant region within the binding site. In particular, it has been hypothesized that inhibitors which lie within this region will tend to resist clinically relevant mutations. The present study offers the first prospective evaluation of this hypothesis, via computational design of inhibitors predicted to conform to the substrate envelope, followed by synthesis and evaluation against wild-type and mutant proteases, as well as structural studies of …

Go to article

Simultaneous Refinement Of The Structure Of Bpti Against Nmr Data Measured In Solution And X-Ray Diffraction Data Measured In Single Crystals, Celia Schiffer, Robert Huber, Kurt Wuthrich, Wilfred Van Gunsteren Nov 2011

Simultaneous Refinement Of The Structure Of Bpti Against Nmr Data Measured In Solution And X-Ray Diffraction Data Measured In Single Crystals, Celia Schiffer, Robert Huber, Kurt Wuthrich, Wilfred Van Gunsteren

Celia A. Schiffer

The structure of the bovine pancreatic trypsin inhibitor (BPTI) has been determined to high resolution by both NMR spectroscopy in solution and X-ray diffraction in crystals. The root-mean-square difference calculated between the two structures for the polypeptide backbone is 0.9 A. Several amino acid side-chains, of which all but one are charged or polar, have different conformations. We find that by refining one structure simultaneously against both the NMR and crystallographic data sets, it can accommodate both. Different starting configurations were used, including the X-ray structure 5pti, an NMR conformer, and the X-ray structure in the full unit cell with …

Go to article

Drug Resistance Against Hcv Ns3/4a Inhibitors Is Defined By The Balance Of Substrate Recognition Versus Inhibitor Binding, Keith P. Romano, Akbar Ali, William E. Royer, Celia A. Schiffer Nov 2011

Drug Resistance Against Hcv Ns3/4a Inhibitors Is Defined By The Balance Of Substrate Recognition Versus Inhibitor Binding, Keith P. Romano, Akbar Ali, William E. Royer, Celia A. Schiffer

Celia A. Schiffer

Hepatitis C virus infects an estimated 180 million people worldwide, prompting enormous efforts to develop inhibitors targeting the essential NS3/4A protease. Resistance against the most promising protease inhibitors, telaprevir, boceprevir, and ITMN-191, has emerged in clinical trials. In this study, crystal structures of the NS3/4A protease domain reveal that viral substrates bind to the protease active site in a conserved manner defining a consensus volume, or substrate envelope. Mutations that confer the most severe resistance in the clinic occur where the inhibitors protrude from the substrate envelope, as these changes selectively weaken inhibitor binding without compromising the binding of substrates. …

Go to article

Computational Design And Experimental Study Of Tighter Binding Peptides To An Inactivated Mutant Of Hiv-1 Protease, Michael Altman, Ellen Nalivaika, Moses Prabu-Jeyabalan, Celia Schiffer, Bruce Tidor Nov 2011

Computational Design And Experimental Study Of Tighter Binding Peptides To An Inactivated Mutant Of Hiv-1 Protease, Michael Altman, Ellen Nalivaika, Moses Prabu-Jeyabalan, Celia Schiffer, Bruce Tidor

Celia A. Schiffer

Drug resistance in HIV-1 protease, a barrier to effective treatment, is generally caused by mutations in the enzyme that disrupt inhibitor binding but still allow for substrate processing. Structural studies with mutant, inactive enzyme, have provided detailed information regarding how the substrates bind to the protease yet avoid resistance mutations; insights obtained inform the development of next generation therapeutics. Although structures have been obtained of complexes between substrate peptide and inactivated (D25N) protease, thermodynamic studies of peptide binding have been challenging due to low affinity. Peptides that bind tighter to the inactivated protease than the natural substrates would be valuable …

Go to article

Design And Synthesis Of Hiv-1 Protease Inhibitors Incorporating Oxazolidinones As P2/P2' Ligands In Pseudosymmetric Dipeptide Isosteres, G. S. Kiran Kumar Reddy, Akbar Ali, Madhavi Nalam, Saima Anjum, Hong Cao, Robin Nathans, Celia Schiffer, Tariq Rana Nov 2011

Design And Synthesis Of Hiv-1 Protease Inhibitors Incorporating Oxazolidinones As P2/P2' Ligands In Pseudosymmetric Dipeptide Isosteres, G. S. Kiran Kumar Reddy, Akbar Ali, Madhavi Nalam, Saima Anjum, Hong Cao, Robin Nathans, Celia Schiffer, Tariq Rana

Celia A. Schiffer

A series of novel HIV-1 protease inhibitors based on two pseudosymmetric dipeptide isosteres have been synthesized and evaluated. The inhibitors were designed by incorporating N-phenyloxazolidinone-5-carboxamides into the hydroxyethylene and (hydroxyethyl)hydrazine dipeptide isosteres as P2 and P2' ligands. Compounds with (S)-phenyloxazolidinones attached at a position proximal to the central hydroxyl group showed low nM inhibitory activities against wild-type HIV-1 protease. Selected compounds were further evaluated for their inhibitory activities against a panel of multidrug-resistant protease variants and for their antiviral potencies in MT-4 cells. The crystal structures of lopinavir (LPV) and two new inhibitors containing phenyloxazolidinone-based ligands in complex with wild-type …

Go to article

Structural Stability Of Disulfide Mutants Of Basic Pancreatic Trypsin Inhibitor: A Molecular Dynamics Study, Celia Schiffer, Wilfred Van Gunsteren Nov 2011

Structural Stability Of Disulfide Mutants Of Basic Pancreatic Trypsin Inhibitor: A Molecular Dynamics Study, Celia Schiffer, Wilfred Van Gunsteren

Celia A. Schiffer

The structure and folding of basic pancreatic trypsin inhibitor (BPTI) has been studied extensively by experimental means. We report a computer simulation study of the structural stability of various disulfide mutants of BPTI, involving eight 250-psec molecular dynamics simulations of the proteins in water, with and without a phosphate counterion. The presence of the latter alters the relative stability of the single disulfide species [5-55] and [30-51]. This conclusion can explain results of mutational studies and the conservation of residues in homologues of BPTI, and suggests a possible role of ions in stabilizing one intermediate over another in unfolding or …

Go to article

Evaluating The Substrate-Envelope Hypothesis: Structural Analysis Of Novel Hiv-1 Protease Inhibitors Designed To Be Robust Against Drug Resistance, Madhavi Nalam, Akbar Ali, Michael Altman, G. S. Kiran Kumar Reddy, Sripriya Chellappan, Visvaldas Kairys, Aysegul Ozen, Hong Cao, Michael Gilson, Bruce Tidor, Tariq Rana, Celia Schiffer Nov 2011

Evaluating The Substrate-Envelope Hypothesis: Structural Analysis Of Novel Hiv-1 Protease Inhibitors Designed To Be Robust Against Drug Resistance, Madhavi Nalam, Akbar Ali, Michael Altman, G. S. Kiran Kumar Reddy, Sripriya Chellappan, Visvaldas Kairys, Aysegul Ozen, Hong Cao, Michael Gilson, Bruce Tidor, Tariq Rana, Celia Schiffer

Celia A. Schiffer

Drug resistance mutations in HIV-1 protease selectively alter inhibitor binding without significantly affecting substrate recognition and cleavage. This alteration in molecular recognition led us to develop the substrate-envelope hypothesis which predicts that HIV-1 protease inhibitors that fit within the overlapping consensus volume of the substrates are less likely to be susceptible to drug-resistant mutations, as a mutation impacting such inhibitors would simultaneously impact the processing of substrates. To evaluate this hypothesis, over 130 HIV-1 protease inhibitors were designed and synthesized using three different approaches with and without substrate-envelope constraints. A subset of 16 representative inhibitors with binding affinities to wild-type …

Go to article

Structure Of A Phage Display-Derived Variant Of Human Growth Hormone Complexed To Two Copies Of The Extracellular Domain Of Its Receptor: Evidence For Strong Structural Coupling Between Receptor Binding Sites, Celia Schiffer, Mark Ultsch, Scott Walsh, William Somers, Abraham De Vos, Anthony Kossiakoff Nov 2011

Structure Of A Phage Display-Derived Variant Of Human Growth Hormone Complexed To Two Copies Of The Extracellular Domain Of Its Receptor: Evidence For Strong Structural Coupling Between Receptor Binding Sites, Celia Schiffer, Mark Ultsch, Scott Walsh, William Somers, Abraham De Vos, Anthony Kossiakoff

Celia A. Schiffer

The structure of the ternary complex between the phage display- optimized, high-affinity Site 1 variant of human growth hormone (hGH) and two copies of the extracellular domain (ECD) of the hGH receptor (hGHR) has been determined at 2.6 A resolution. There are widespread and significant structural differences compared to the wild-type ternary hGH hGHR complex. The hGH variant (hGH(v)) contains 15 Site 1 mutations and binds>10(2) tighter to the hGHR ECD (hGH(R1)) at Site 1. It is biologically active and specific to hGHR. The hGH(v) Site 1 interface is somewhat smaller and 20% more hydrophobic compared to the wild-type …

Go to article

Combating Susceptibility To Drug Resistance: Lessons From Hiv-1 Protease, Nancy King, Moses Prabu-Jeyabalan, Ellen Nalivaika, Celia Schiffer Nov 2011

Combating Susceptibility To Drug Resistance: Lessons From Hiv-1 Protease, Nancy King, Moses Prabu-Jeyabalan, Ellen Nalivaika, Celia Schiffer

Celia A. Schiffer

Drug resistance is a major obstacle in modern medicine. However, resistance is rarely considered in drug development and may inadvertently be facilitated, as many designed inhibitors contact residues that can mutate to confer resistance, without significantly impairing function. Contemporary drug design often ignores the detailed atomic basis for function and primarily focuses on disrupting the target's activity, which is necessary but not sufficient for developing a robust drug. In this study, we examine the impact of drug-resistant mutations in HIV-1 protease on substrate recognition and demonstrate that most primary active site mutations do not extensively contact substrates, but are critical …

Go to article

Time-Averaging Crystallographic Refinement: Possibilities And Limitations Using Alpha-Cyclodextrin As A Test System, Celia A. Schiffer, P. Gros, Wilfred F. Van Gunsteren Nov 2011

Time-Averaging Crystallographic Refinement: Possibilities And Limitations Using Alpha-Cyclodextrin As A Test System, Celia A. Schiffer, P. Gros, Wilfred F. Van Gunsteren

Celia A. Schiffer

The method of time-averaging crystallographic refinement is assessed using a small molecule, alpha-cyclodextrin, as a test system. A total of 16 refinements are performed on simulated data. Three resolution ranges of the data are used, the memory relaxation time of the averaging is varied, and several overall temperature factors are used. The most critical factor in the reliable application of time-averaging is the resolution of the data. The ratio of data to molecular degrees of freedom should be large enough to avoid overfitting of the data by the time-averaging procedure. The use of a free R-factor can aid in determining …

Go to article

Decomposing The Energetic Impact Of Drug Resistant Mutations In Hiv-1 Protease On Binding Drv, Yufeng Cai, Celia Schiffer Nov 2011

Decomposing The Energetic Impact Of Drug Resistant Mutations In Hiv-1 Protease On Binding Drv, Yufeng Cai, Celia Schiffer

Celia A. Schiffer

Darunavir (DRV) is a high affinity (4.5x10(-12) M, DeltaG = -15.2 kcal/mol) HIV-1 protease inhibitor. Two drug-resistant protease variants FLAP+ (L10I, G48V, I54V, V82A) and ACT (V82T, I84V) decrease the binding affinity with DRV by 1.0 kcal/mol and 1.6 kcal/mol respectively. In this study the absolute and relative binding free energies of DRV with wild-type protease, FLAP+ and ACT were calculated with MM-PB/GBSA and thermodynamic integration methods, respectively. Free energy decomposition elucidated that the mutations conferred resistance by distorting the active site of HIV-1 protease so that the residues that lost binding free energy were not limited to the sites …

Go to article

Replacement Of The P1 Amino Acid Of Human Immunodeficiency Virus Type 1 Gag Processing Sites Can Inhibit Or Enhance The Rate Of Cleavage By The Viral Protease, Steve Pettit, Gavin Henderson, Celia Schiffer, Ronald Swanstrom Nov 2011

Replacement Of The P1 Amino Acid Of Human Immunodeficiency Virus Type 1 Gag Processing Sites Can Inhibit Or Enhance The Rate Of Cleavage By The Viral Protease, Steve Pettit, Gavin Henderson, Celia Schiffer, Ronald Swanstrom

Celia A. Schiffer

Processing of the human immunodeficiency virus type 1 (HIV-1) Gag precursor is highly regulated, with differential rates of cleavage at the five major processing sites to give characteristic processing intermediates. We examined the role of the P1 amino acid in determining the rate of cleavage at each of these five sites by using libraries of mutants generated by site-directed mutagenesis. Between 12 and 17 substitution mutants were tested at each P1 position in Gag, using recombinant HIV-1 protease (PR) in an in vitro processing reaction of radiolabeled Gag substrate. There were three sites in Gag (MA/CA, CA/p2, NC/p1) where one …

Go to article

Hiv-1 Protease Inhibitors From Inverse Design In The Substrate Envelope Exhibit Subnanomolar Binding To Drug-Resistant Variants, Michael Altman, Akbar Ali, G. S. Kiran Kumar Reddy, Madhavi Nalam, Saima Anjum, Hong Cao, Sripriya Chellappan, Visvaldas Kairys, Miguel Fernandes, Michael Gilson, Celia Schiffer, Tariq Rana, Bruce Tidor Nov 2011

Hiv-1 Protease Inhibitors From Inverse Design In The Substrate Envelope Exhibit Subnanomolar Binding To Drug-Resistant Variants, Michael Altman, Akbar Ali, G. S. Kiran Kumar Reddy, Madhavi Nalam, Saima Anjum, Hong Cao, Sripriya Chellappan, Visvaldas Kairys, Miguel Fernandes, Michael Gilson, Celia Schiffer, Tariq Rana, Bruce Tidor

Celia A. Schiffer

The acquisition of drug-resistant mutations by infectious pathogens remains a pressing health concern, and the development of strategies to combat this threat is a priority. Here we have applied a general strategy, inverse design using the substrate envelope, to develop inhibitors of HIV-1 protease. Structure-based computation was used to design inhibitors predicted to stay within a consensus substrate volume in the binding site. Two rounds of design, synthesis, experimental testing, and structural analysis were carried out, resulting in a total of 51 compounds. Improvements in design methodology led to a roughly 1000-fold affinity enhancement to a wild-type protease for the …

Go to article

The Effect Of Clade-Specific Sequence Polymorphisms On Hiv-1 Protease Activity And Inhibitor Resistance Pathways, Rajintha Bandaranayake, Madhavi Kolli, Nancy King, Ellen Nalivaika, Annie Heroux, Junko Kakizawa, Wataru Sugiura, Celia Schiffer Nov 2011

The Effect Of Clade-Specific Sequence Polymorphisms On Hiv-1 Protease Activity And Inhibitor Resistance Pathways, Rajintha Bandaranayake, Madhavi Kolli, Nancy King, Ellen Nalivaika, Annie Heroux, Junko Kakizawa, Wataru Sugiura, Celia Schiffer

Celia A. Schiffer

The majority of HIV-1 infections around the world result from non-B clade HIV-1 strains. The CRF01_AE (AE) strain is seen principally in Southeast Asia. AE protease differs by approximately 10% in amino acid sequence from clade B protease and carries several naturally occurring polymorphisms that are associated with drug resistance in clade B. AE protease has been observed to develop resistance through a nonactive-site N88S mutation in response to nelfinavir (NFV) therapy, whereas clade B protease develops both the active-site mutation D30N and the nonactive-site mutation N88D. Structural and biochemical studies were carried out with wild-type and NFV-resistant clade B …

Go to article

Lack Of Synergy For Inhibitors Targeting A Multi-Drug-Resistant Hiv-1 Protease, Nancy King, Laurence Melnick, Moses Prabu-Jeyabalan, Ellen Nalivaika, Shiow-Shong Yang, Yun Gao, Xiaoyi Nie, Charles Zepp, Donald Heefner, Celia Schiffer Nov 2011

Lack Of Synergy For Inhibitors Targeting A Multi-Drug-Resistant Hiv-1 Protease, Nancy King, Laurence Melnick, Moses Prabu-Jeyabalan, Ellen Nalivaika, Shiow-Shong Yang, Yun Gao, Xiaoyi Nie, Charles Zepp, Donald Heefner, Celia Schiffer

Celia A. Schiffer

The three-dimensional structures of indinavir and three newly synthesized indinavir analogs in complex with a multi-drug-resistant variant (L63P, V82T, I84V) of HIV-1 protease were determined to approximately 2.2 A resolution. Two of the three analogs have only a single modification of indinavir, and their binding affinities to the variant HIV-1 protease are enhanced over that of indinavir. However, when both modifications were combined into a single compound, the binding affinity to the protease variant was reduced. On close examination, the structural rearrangements in the protease that occur in the tightest binding inhibitor complex are mutually exclusive with the structural rearrangements …

Go to article

Prediction Of Homologous Protein Structures Based On Conformational Searches And Energetics, Celia Schiffer, James Caldwell, Peter Kollman, Robert Stroud Nov 2011

Prediction Of Homologous Protein Structures Based On Conformational Searches And Energetics, Celia Schiffer, James Caldwell, Peter Kollman, Robert Stroud

Celia A. Schiffer

A "knowledge-based" method of predicting the unknown structure of a protein from a homologous known structure using energetics to determine a sidechain conformation is proposed. The method consists of exchanging the residues in the known structure for the sequence of the unknown protein. Then a conformational search with molecular mechanics energy minimization is done on the exchanged residues. The lowest energy conformer is the one picked to be the predicted structure. In the structure of bovine trypsin, the importance of including a solvation energy term in the search is demonstrated for solvent accessible residues, while molecular mechanics alone is enough …

Go to article

Crystallization Of Human Thymidylate Synthase, Celia Schiffer, V. Jo Davisson, Daniel Santi, Robert Stroud Nov 2011

Crystallization Of Human Thymidylate Synthase, Celia Schiffer, V. Jo Davisson, Daniel Santi, Robert Stroud

Celia A. Schiffer

Human thymidylate synthase has been crystallized in the absence of ligands and diffracts beyond 3.0 A. The protein was cloned and expressed in Escherichia coli and then crystallized from ammonium sulfate in the presence of beta-mercaptoethanol at a variety of pH values. The crystals are trigonal in the space-group P3(1)21; the unit cell dimensions are a = b = 96.7 A, c = 84.1 A.

Go to article

Human Immunodeficiency Virus Type 1 Protease-Correlated Cleavage Site Mutations Enhance Inhibitor Resistance, Madhavi Kolli, Eric Stawiski, Colombe Chappey, Celia Schiffer Nov 2011

Human Immunodeficiency Virus Type 1 Protease-Correlated Cleavage Site Mutations Enhance Inhibitor Resistance, Madhavi Kolli, Eric Stawiski, Colombe Chappey, Celia Schiffer

Celia A. Schiffer

Drug resistance is an important cause of antiretroviral therapy failure in human immunodeficiency virus (HIV)-infected patients. Mutations in the protease render the virus resistant to protease inhibitors (PIs). Gag cleavage sites also mutate, sometimes correlating with resistance mutations in the protease, but their contribution to resistance has not been systematically analyzed. The present study examines mutations in Gag cleavage sites that associate with protease mutations and the impact of these associations on drug susceptibilities. Significant associations were observed between mutations in the nucleocapsid-p1 (NC-p1) and p1-p6 cleavage sites and various PI resistance-associated mutations in the protease. Several patterns were frequently …

Go to article

Three Residues In Hiv-1 Matrix Contribute To Protease Inhibitor Susceptibility And Replication Capacity, Chris Parry, Madhavi Kolli, Richard Myers, Patricia Cane, Celia Schiffer, Deenan Pillay Nov 2011

Three Residues In Hiv-1 Matrix Contribute To Protease Inhibitor Susceptibility And Replication Capacity, Chris Parry, Madhavi Kolli, Richard Myers, Patricia Cane, Celia Schiffer, Deenan Pillay

Celia A. Schiffer

Other than cleavage site mutations, there is little data on specific positions within Gag that impact on HIV protease inhibitor susceptibility. We have recently shown that non-cleavage site mutations in gag, particularly within matrix protein can restore replication capacity and further reduce protease inhibitor drug susceptibility when coexpressed with a drug-resistant (mutant) protease. The matrix protein of this patient-derived virus was studied in order to identify specific changes responsible for this phenotype. Three amino acid changes in matrix (R76K, Y79F, and T81A) had an impact on replication capacity as well as drug susceptibility. Introduction of these three changes into wild-type …

Go to article

Discovery And Selection Of Tmc114, A Next Generation Hiv-1 Protease Inhibitor, Dominique Surleraux, Abdellah Tahri, Wim Verschueren, Geert Pille, Herman De Kock, Tim Jonckers, Anik Peeters, Sandra De Meyer, Hilde Azijn, Rudi Pauwels, Marie-Pierre De Bethune, Nancy King, Moses Prabu-Jeyabalan, Celia Schiffer, Piet Wigerinck Nov 2011

Discovery And Selection Of Tmc114, A Next Generation Hiv-1 Protease Inhibitor, Dominique Surleraux, Abdellah Tahri, Wim Verschueren, Geert Pille, Herman De Kock, Tim Jonckers, Anik Peeters, Sandra De Meyer, Hilde Azijn, Rudi Pauwels, Marie-Pierre De Bethune, Nancy King, Moses Prabu-Jeyabalan, Celia Schiffer, Piet Wigerinck

Celia A. Schiffer

The screening of known HIV-1 protease inhibitors against a panel of multi-drug-resistant viruses revealed the potent activity of TMC126 on drug-resistant mutants. In comparison to amprenavir, the improved affinity of TMC126 is largely the result of one extra hydrogen bond to the backbone of the protein in the P2 pocket. Modification of the substitution pattern on the phenylsulfonamide P2' substituent of TMC126 created an interesting SAR, with the close analogue TMC114 being found to have a similar antiviral activity against the mutant and the wild-type viruses. X-ray and thermodynamic studies on both wild-type and mutant enzymes showed an extremely high …

Go to article

Structure-Based Design, Synthesis, And Structure-Activity Relationship Studies Of Hiv-1 Protease Inhibitors Incorporating Phenyloxazolidinones, Akbar Ali, G. S. Kiran Kumar Reddy, Madhavi Nalam, Saima Anjum, Hong Cao, Celia Schiffer, Tariq Rana Nov 2011

Structure-Based Design, Synthesis, And Structure-Activity Relationship Studies Of Hiv-1 Protease Inhibitors Incorporating Phenyloxazolidinones, Akbar Ali, G. S. Kiran Kumar Reddy, Madhavi Nalam, Saima Anjum, Hong Cao, Celia Schiffer, Tariq Rana

Celia A. Schiffer

A series of new HIV-1 protease inhibitors with the hydroxyethylamine core and different phenyloxazolidinone P2 ligands were designed and synthesized. Variation of phenyl substitutions at the P2 and P2' moieties significantly affected the binding affinity and antiviral potency of the inhibitors. In general, compounds with 2- and 4-substituted phenyloxazolidinones at P2 exhibited lower binding affinities than 3-substituted analogues. Crystal structure analyses of ligand-enzyme complexes revealed different binding modes for 2- and 3-substituted P2 moieties in the protease S2 binding pocket, which may explain their different binding affinities. Several compounds with 3-substituted P2 moieties demonstrated picomolar binding affinity and low nanomolar …

Go to article

Accessibility And Order Of Water Sites In And Around Proteins: A Crystallographic Time-Averaging Study, Celia Schiffer, Wilfred Van Gunsteren Nov 2011

Accessibility And Order Of Water Sites In And Around Proteins: A Crystallographic Time-Averaging Study, Celia Schiffer, Wilfred Van Gunsteren

Celia A. Schiffer

Water plays an essential role in most biological processes. Water molecules solvating biomolecules are generally in fast exchange with the environment. Nevertheless, well-defined electron density is seen for water associated with proteins whose crystal structure is determined to high resolution. The relative accessibility of these water sites is likely to be relevant to their biological role but is difficult to assess. A time-averaging crystallographic refinement simulation on basic pancreatic trypsin inhibitor successfully characterizes the relative accessibility of the crystallographic water sites. In such a refinement simulation water diffuses through the crystal lattice in a manner that is consistent with the …

Go to article

First Prev Next Last